Literature DB >> 32920644

Effects of Angiotensin Receptor Blockers (ARBs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected COVID-19.

Abbas Soleimani1, Sina Kazemian2, Shahrokh Karbalai Saleh1, Arya Aminorroaya3,4, Zahra Shajari1, Azar Hadadi5, Mohammad Talebpour6, Hakimeh Sadeghian7, Pooya Payandemehr8, Mehran Sotoodehnia8, Maryam Bahreini8, Farhad Najmeddin9, Ali Heidarzadeh2, Ensieh Zivari10, Haleh Ashraf10,11.   

Abstract

BACKGROUND: There is an ongoing controversy about harms and benefits of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in hypertensive patients with coronavirus disease 2019 (COVID-19). Given the unresolved debate, we investigated the association of ARBs with in-hospital outcomes of these patients.
METHODS: In this retrospective observational study, we studied patients with COVID-19 who referred to Sina Hospital in Tehran, Iran, from 20 February to 29 May 2020. Patients with either positive real-time reverse-transcriptase polymerase-chain-reaction test of swab specimens, or high clinical suspicion according to the World Health Organization's interim guidance were included. We followed-up patients for incurring death, severe COVID-19, and in-hospital complications.
RESULTS: We evaluated 681 patients with COVID-19 of whom 37 patients were excluded due to incomplete medical records and 8 patients who used ACEIs which left 636 patients in the analysis. In this cohort, 108 (17.0%) patients expired and 407 (64.0%) patients incurred severe COVID-19. Of 254 (39.9%) patients with hypertension, 122 (48.0%) patients were receiving an ARB. After adjustment for possible confounders, we found no independent association between taking ARBs and in-hospital outcomes except for acute kidney injury (AKI), in patients with confirmed or clinically suspected COVID-19, either hypertensive or not-hypertensive. We found that discontinuation of ARBs during hospitalization was associated with a greater risk of mortality, invasive ventilation, and AKI (all P ˂ 0.002).
CONCLUSIONS: We found that taking ARBs by patients with hypertension and confirmed or clinically suspected COVID-19 is not associated with poorer in-hospital outcomes after adjustment for possible confounders. © American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; blood pressure; hypertension; renin–angiotensin system

Year:  2020        PMID： 32920644      PMCID： PMC7543264          DOI： 10.1093/ajh/hpaa149

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN： 0895-7061            Impact factor:   2.689


  16 in total

Review 1.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

Review 2.  Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.

Authors:  Jordan Loader; Frances C Taylor; Erik Lampa; Johan Sundström
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

3.  Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.

Authors:  Sandeep Singh; Annette K Offringa-Hup; Susan J J Logtenberg; Paul D Van der Linden; Wilbert M T Janssen; Hubertina Klein; Femke Waanders; Suat Simsek; Cornelis P C de Jager; Paul Smits; Machteld van der Feltz; Gerrit Jan Beumer; Christine Widrich; Martijn Nap; Sara-Joan Pinto-Sietsma
Journal:  Hypertension       Date:  2021-06-09       Impact factor: 10.190

Review 4.  Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.

Authors:  Mariana Alves; Marília Andreia Fernandes; Gülistan Bahat; Athanase Benetos; Hugo Clemente; Tomasz Grodzicki; Manuel Martínez-Sellés; Francesco Mattace-Raso; Chakravarthi Rajkumar; Andrea Ungar; Nikos Werner; Timo E Strandberg
Journal:  Eur Geriatr Med       Date:  2021-05-25       Impact factor: 1.710

5.  Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.

Authors:  Masoud Nouri-Vaskeh; Niusha Kalami; Ramin Zand; Zahra Soroureddin; Mojtaba Varshochi; Khalil Ansarin; Haleh Rezaee; Ali Taghizadieh; Armin Sadeghi; Masoud Ahangari Maleki; Azam Esmailnajad; Parviz Saleh; Mehdi Haghdoost; Mehdi Maleki; Akbar Sharifi
Journal:  Int J Clin Pract       Date:  2021-03-13       Impact factor: 3.149

6.  The Interplay Between the Immune System, the Renin-Angiotensin-Aldosterone System (RAAS), and RAAS Inhibitors May Modulate the Outcome of COVID-19: A Systematic Review.

Authors:  Hiba Naveed; Abdallah Elshafeey; Dana Al-Ali; Emmad Janjua; Areej Nauman; Hussam Kawas; Ridhima Kaul; Arwa Saed Aldien; Mohamed B Elshazly; Dalia Zakaria
Journal:  J Clin Pharmacol       Date:  2021-04-07       Impact factor: 2.860

7.  Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.

Authors:  Francisco J de Abajo; Antonio Rodríguez-Miguel; Sara Rodríguez-Martín; Victoria Lerma; Alberto García-Lledó
Journal:  BMC Med       Date:  2021-05-12       Impact factor: 8.775

8.  Mortality and Severity in COVID-19 Patients on ACEIs and ARBs-A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.

Authors:  Romil Singh; Sawai Singh Rathore; Hira Khan; Abhishek Bhurwal; Mack Sheraton; Prithwish Ghosh; Sohini Anand; Janaki Makadia; Fnu Ayesha; Kiran S Mahapure; Ishita Mehra; Aysun Tekin; Rahul Kashyap; Vikas Bansal
Journal:  Front Med (Lausanne)       Date:  2022-01-10

9.  Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: a systematic review and meta-analysis.

Authors:  Sul A Lee; Robin Park; Ji Hyun Yang; In Kyung Min; Jung Tak Park; Seung Hyeok Han; Shin-Wook Kang; Tae-Hyun Yoo
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

10.  Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis.

Authors:  Na Jia; Guifang Zhang; Xuelin Sun; Yan Wang; Sai Zhao; Wenjie Chi; Sitong Dong; Jun Xia; Ping Zeng; Deping Liu
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-07-28       Impact factor: 2.885
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.